ライフサイエンスコーパス: KCN

1 KCN formulae and TK are useful for intraocular lens powe

2 KCN formulae had the lowest RMSEs in all eyes, and BU2 K

3 KCN had no effect on endothelial cell ATP content or bar

4 KCN profoundly impacts VRQoL, exceeding the effects of r

5 KCN titration assays, carried out on intact uncoupled ce

6 Grade 2 KCN showed the highest prevalence at 26.4% (N = 33), whi

7 me from the reaction mixture of HRP/H(2)O(2)/KCN was unambiguously identified as cyanoheme by the obs

8 , Cooke K6, EVO 2.0, Kane, and Pearl-DGS), 3 KCN formulae (BU2 KCN: M-PCA, BU2 KCN: P-PCA, and Kane K

9 ondrial function with rotenone, antimycin A, KCN, carbonylcyanide-m-chlorophenylhydrazone, or oligomy

10 elevated in pKCN patients, similar to adult KCN cases.

11 icantly influences VRQoL, with more advanced KCN generally linked to lower QoL scores, although this

12 sion injury (pH paradox) was prevented after KCN washout at pH 6.2.

13 E2 was ineffective against KCN and oligomycin-induced cell death.

14 , and BU2 KCN:M-PCA performed the best among KCN formulae in all subgroups.

15 iodemographic differences in treatment among KCN patients may reflect differences in access, use, or

16 were inhibited by flavone, antimycin A, and KCN but not by rotenone.

17 n added to SMP pretreated with ascorbate and KCN to reduce the high potential components (iron-sulfur

18 > 0.90 (95% CI: 0.81, 1.0) for DES, FED, and KCN, respectively.

19 Both 3-NPA and KCN (10 microM-1 mM) reduced neuronal viability in a con

20 onships between time needed for recovery and KCN concentration, duration of exposure and number of co

21 urbations (confluence, serum starvation, and KCN treatment) are all expected to result in an increase

22 yanide p-trifluoromethoxyphenylhydrazone and KCN.

23 rial inhibitors, rotenone, 3-NPA, antimycin, KCN, and oligomycin, exhibited concentration dependent t

24 There was no association between KCN and allergic rhinitis, mitral valve disorder, aortic

25 However, no significant relationship between KCN exposure and long-term survival has been found.

26 ae had the lowest RMSEs in all eyes, and BU2 KCN:M-PCA performed the best among KCN formulae in all s

27 0, Kane, and Pearl-DGS), 3 KCN formulae (BU2 KCN: M-PCA, BU2 KCN: P-PCA, and Kane KCN), and H1 with e

28 rl-DGS), 3 KCN formulae (BU2 KCN: M-PCA, BU2 KCN: P-PCA, and Kane KCN), and H1 with equivalent kerato

29 The BU2 KCN: M-PCA using TK values performed best for eyes with

30 e KCN, if TK values are unavailable, the BU2 KCN: P-PCA performed better than the top-ranked non-KCN

31 nfluence the extent of cell death induced by KCN/2-DG.

32 O(2) uptake that was completely inhibited by KCN and antimycin A.

33 insensitive to piericidin A but inhibited by KCN.

34 Labeling experiments with [(1)(3)C]KCN demonstrated that the altered CN tolerance could be

35 tively from the readily available [(13/14)C]-KCN.

36 Inhibition of mitochondria with CCCP, KCN, or rotenone blocked intracellular ATP production, A

37 ion stoichiometry and the potassium cyanide (KCN) induced cleavage of the protein suggested that all

38 Potassium cyanide (KCN) is a highly lethal poison with cyanide anions havin

39 Potassium cyanide (KCN) treatment and serum starvation of cells yielded sim

40 of cytochrome c oxidase, potassium cyanide (KCN), should compete with LED and reduce its beneficial

41 ropionic acid (3-NPA) and potassium cyanide (KCN), with the production of reactive molecular species

42 imycin A, and 1 and 10 mM potassium cyanide (KCN).

43 he effects of gaseous NO, potassium cyanide (KCN, a mitochondrial respiratory chain inhibitor) and io

44 were designed to avoid the rather dangerous KCN treatment step for the removal of conductive minor p

45 ic acid or potassium cyanide/2-deoxyglucose (KCN/2-DG) for varying lengths of time, and cell death wa

46 s that can be used to automatically diagnose KCN, FED, and DES using only AS-OCT images.

47 drome patients with and without KCN (24 Down-KCN and 204 Down-nonKCN eyes) and normal age- and gender

48 and corneal volume (P = 0.519) between Down-KCN and Down-nonKCN groups; these inter-group densitomet

49 In Down-KCN, Down-nonKCN, and control groups, respectively, mean

50 2 +/- 0.8; fed + KCN, 32.1 +/- 0.9; fasted + KCN, 0.2 +/- 0.2 micromol x g(-1) x h(-1).

51 ed, 15.1 +/- 2.4; fasted, 4.2 +/- 0.8; fed + KCN, 32.1 +/- 0.9; fasted + KCN, 0.2 +/- 0.2 micromol x

52 of a chiral cyanide ion source, derived from KCN and quaternary ammonium bromide derived from cinchon

53 ge 14.4 years), 4 (1.32%) were found to have KCN, and 4 (1.32%) were KC suspects.

54 nd-organ damage had 52% lower odds of having KCN (adjusted OR, 0.48; 95% CI, 0.40-0.58; P < 0.001) co

55 However, KCN had no effect on total pimonidazole adducts detected

56 and diabetes was less common (P < .0001), in KCN patients.

57 a potential indicator of disease activity in KCN patients.

58 l for intraocular lens power calculations in KCN eyes, especially in eyes with severe KCN.

59 ty is energy dependent: it did not happen in KCN-treated cells.

60 ae (BU2 KCN: M-PCA, BU2 KCN: P-PCA, and Kane KCN), and H1 with equivalent keratometry reading values

61 Keratoconus (KCN) and Down syndrome affect the corneal density and vo

62 Keratoconus (KCN) is a common ectatic disorder of the cornea.

63 Keratoconus (KCN) is characterized by corneal thinning and bulging, l

64 Keratoconus (KCN), a progressive ectatic corneal disorder, significan

65 , sociodemographic factors, and keratoconus (KCN) among a large, diverse group of insured individuals

66 treatment in patients who have keratoconus (KCN) and post-refractive surgery ectasia were included.

67 Investigate trends in keratoconus (KCN) treatment patterns and diagnosis age from 2015 to 2

68 tical parameters in progressive keratoconus (KCN) cases.

69 l and topographical evaluation: the manifest KCN group (n = 30), the subclinical KCN group (n = 32),

70 atistically higher in patients with manifest KCN, subclinical KCN, and topographically normal KCN rel

71 tored neuronal ATP content only at 10 microm KCN but not at higher concentrations of KCN tested.

72 y of LED during exposure to 10 or 100 microm KCN but did not restore enzyme activity to control level

73 red enzyme activity blocked by 10-100 microm KCN.

74 ed neuronal cell death induced by 300 microm KCN from 83.6 to 43.5%.

75 ubation with either N2, antimycin A, or 1 mM KCN in comparison with their appearance under oxygenated

76 s impaired (as with N2, antimycin A, or 1 mM KCN) photoreceptor cells are resistant to short-term epi

77 e presence of N2, 0.01 mM antimycin, or 1 mM KCN, lactic acid production was linear throughout the 60

78 bations with either N2, antimycin A, or 1 mM KCN.

79 We found that exposure to 1 mM KCN/2 mM 2-DG for 2 h produced consistent delayed cell d

80 With 10 mM KCN (pH 8.9), retinal lactate production was severely de

81 The deleterious effects of 10 mM KCN on these parameters were lessened to varying degrees

82 In contrast, use of 10 mM KCN produced an entirely different set of results.

83 olated rat retinas to media containing 10 mM KCN results from the inhibition of both respiration and

84 upted after incubation of retinas with 10 mM KCN.

85 However, at 1-100 mm KCN, the protective effects of LED decreased, and neuron

86 ion at 0 degreesC or in the presence of 2 mM KCN abolished high-affinity iron uptake, suggesting that

87 Patients with a new KCN diagnosis from 2015 to 2020 were identified in the A

88 PCA performed better than the top-ranked non-KCN formula (SRK/T).

89 In eyes with nonsevere KCN, if TK values are unavailable, EVO 2.0 K was statist

90 For eyes with nonsevere KCN, the EVO 2.0 TK or K can also be used.

91 subclinical KCN, and topographically normal KCN relatives compared with controls.

92 e irrespective of the presence or absence of KCN.

93 Upon addition of KCN to Cu-grown cells, the brownish coloration was bleac

94 scence increase in darkness upon addition of KCN, was much less in DeltandhD1/D2 and M55 than in Delt

95 A 25-year-old man known case of KCN was referred with complaints about blurred vision an

96 ne pH (8.9) found when this concentration of KCN was simply added to bicarbonate-buffered media and a

97 and glycolysis by this high concentration of KCN.

98 crom KCN but not at higher concentrations of KCN tested.

99 The average age (standard deviation) of KCN patients decreased from 44.1 (+/-16.9) years in 2015

100 l of 66 199 patients with a new diagnosis of KCN were identified.

101 ion of Diseases, Tenth Revision diagnosis of KCN, and 1612 ophthalmology patients as a control group.

102 The large number of KCN genes for potassium channel subunits and the heterog

103 lagen vascular disease had 35% lower odds of KCN (adjusted OR, 0.65; 95% CI, 0.47-0.91; P = 0.01).

104 diabetes mellitus (DM) had 20% lower odds of KCN (adjusted OR, 0.80; 95% CI, 0.71-0.90; P = 0.002), a

105 r conditions found to have increased odds of KCN included sleep apnea (adjusted OR, 1.13; 95% CI, 1.0

106 rtain systemic diseases affected the odds of KCN.

107 oquinone pool in darkness in the presence of KCN was up to fivefold slower in the mutants than in the

108 In the presence of KCN, leaf tissue of either mutant or wild-type AOX overe

109 is effective in reducing the progression of KCN and post-laser refractive surgery ectasia in most tr

110 ealth with a control group with no record of KCN.

111 Health records of KCN patients <65 years of age from 2011 to 2018 were obt

112 Patients with DM have lower risk of KCN, potentially because of corneal glycosylation.

113 rformed best for eyes with all severities of KCN.

114 s, including exposure to aqueous solution of KCN.

115 Herein, stocks of KCN and NaCN were analyzed for trace anions by high perf

116 raphic disparities exist in the treatment of KCN.

117 estored to pH 7.4 with or without washout of KCN (simulated reperfusion).

118 no protective effect at all against 3-NPA or KCN toxicity at concentrations up to 1 mM.

119 essing choroidal thickness (CT) in pediatric KCN ( pKCN) patients can provide insights for better und

120 Progressive KCN cases cope with some ocular surface problems, such a

121 Thirty eyes of 25 progressive KCN cases needing corneal CXL entered the study.

122 e of epithelium-off CXL to treat progressive KCN (5 studies) and post-laser refractive surgery ectasi

123 In eyes with severe KCN, if TK values are unavailable, the BU2 KCN: P-PCA pe

124 in KCN eyes, especially in eyes with severe KCN.

125 Similarly, KCN titration assays on digitonin-permeabilized cells ha

126 , and 200 mg/kg/day) inhibited growth of SMS-KCN-69n tumor xenografts in a dose-dependent fashion, wi

127 The addition of small amounts of solid KCN to solution and solid-phase esters in THF/MeOH/50% a

128 r in patients with manifest KCN, subclinical KCN, and topographically normal KCN relatives compared w

129 manifest KCN group (n = 30), the subclinical KCN group (n = 32), the KCN relatives group (n = 53), an

130 Ultimately, successful KCN management hinges on a balance of objective visual i

131 ng alternative sources of cyanide other than KCN/HCN or TMSCN for this important reaction.

132 30), the subclinical KCN group (n = 32), the KCN relatives group (n = 53), and the control group (n =

133 fully consistent with those obtained in the KCN titration experiments.

134 A study of the influence of water on the KCN-catalyzed cross silyl benzoin addition revealed more

135 y, a new protocol for tardigrade exposure to KCN has been devised.

136 macrobiotus experimentalis were subjected to KCN exposures of various concentrations and durations, a

137 lts confirm high tolerance of tardigrades to KCN.

138 82 (3.0%) patients had keratoplasty to treat KCN.

139 eta,gamma,delta-unsaturated acylsilanes with KCN under phase-transfer catalyst conditions using n-Bu4

140 ing the mitochondrial respiratory chain with KCN decreased protein-bound pimonidazole adducts.

141 When the receiving arm is charged with KCN, transport is much faster (ca. 100 h) and higher K2M

142 .50-0.75; P < 0.001) of being diagnosed with KCN compared with whites.

143 .26-1.62; P < 0.001) of being diagnosed with KCN compared with whites.

144 anolysis of the DTNB-inactivated enzyme with KCN led to the elimination of 2 equiv of 5-thio-2-nitrob

145 elial cells exposed to chemical hypoxia with KCN (2.5 mmol/L) to simulate the adenosine triphosphate

146 ere obtained when SMP were treated only with KCN or NaN(3), reagents that inhibit cytochrome oxidase,

147 ol (or MOA-stilbene or stigmatellin) or with KCN and ascorbate to reduce the high potential centers o

148 Of 42,086 total patients with KCN identified, 1282 (3.0%) patients had keratoplasty to

149 analysis of a large sample of patients with KCN reveals previously unidentified risk factors associa

150 Sixteen thousand fifty-three patients with KCN were matched 1:1 with persons without KCN.

151 In Down patients with KCN, the increased light scatter and density in the 6 mm

152 Clinicians caring for persons with KCN should inquire about breathing or sleeping and, when

153 Persons with KCN were identified using billing codes and matched by a

154 Imines were reacted with KCN/NH(4)Cl in aqueous ethanol to produce alpha-arylamin

155 ansformed, but not overexpressor, roots with KCN treatment.

156 c oxidase, and wild type cells treated with KCN (a cytochrome c oxidase inhibitor).

157 uded Down syndrome patients with and without KCN (24 Down-KCN and 204 Down-nonKCN eyes) and normal ag

158 th KCN were matched 1:1 with persons without KCN.